Syneos Health (Syneos Health) Operating Income : $343 Mil (TTM As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Syneos Health Operating Income?

Syneos Health's Operating Income for the three months ended in Jun. 2023 was $53 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $343 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Syneos Health's Operating Income for the three months ended in Jun. 2023 was $53 Mil. Syneos Health's Revenue for the three months ended in Jun. 2023 was $1,366 Mil. Therefore, Syneos Health's Operating Margin % for the quarter that ended in Jun. 2023 was 3.87%.

Good Sign:

Syneos Health Inc operating margin is expanding. Margin expansion is usually a good sign.

Syneos Health's 5-Year average Growth Rate for Operating Margin % was 8.10% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Syneos Health's annualized ROC % for the quarter that ended in Jun. 2023 was 3.51%. Syneos Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 44.73%.

Syneos Health Operating Income Historical Data

The historical data trend for Syneos Health's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneos Health Operating Income Chart

Syneos Health Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Income

Get a 7-Day Free Trial

275.82

279.89

322.56

412.10

459.83

Syneos Health Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Operating Income	Get a 7-Day Free Trial															125.58	126.57	118.23	45.15	52.86

Syneos Health Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $343 Mil.

Syneos Health (NAS:SYNH) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Syneos Health's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	211.448 * ( 1 - -19.97% )	/	( (7223.778	+	7238.252)	/ 2 )
=	253.6741656	/	7231.015
=	3.51 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8098.776	-	764.058	-	( 110.94	-	max(0, 1687.9	-	1946.278	+	110.94	))
=	7223.778

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8075.381	-	754.962	-	( 82.167	-	max(0, 1627.158	-	1951.76	+	82.167	))
=	7238.252

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Syneos Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	154.152	/	( ( (356.619 + max(-559.755, 0))	+	(332.648 + max(-497.579, 0)) )	/	2 )
=	154.152	/	( ( 356.619	+	332.648 )	/	2 )
=	154.152	/	344.6335
=	44.73 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(879.249	+	0	+	184.435)	-	(764.058	+	859.381	+	0)
=	-559.755

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(891.249	+	0	+	170.056)	-	(754.962	+	803.922	+	0)
=	-497.579

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Syneos Health's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	52.862	/	1366.08
	=	3.87 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Syneos Health Operating Income Related Terms

Thank you for viewing the detailed overview of Syneos Health's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Syneos Health (Syneos Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Syneos Health Inc (NAS:SYNH) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1030 Sync Street, Morrisville, NC, USA, 27560-5468

Website

https://www.syneoshealth.com

Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Executives

Michael J. Bonello	officer: Chief Financial Officer	4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Stanford Rudnick	officer: See remarks	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Christian Tucat	officer: Chief Business Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Michael Lee Brooks	officer: See remarks	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jonathan Olefson	officer: General Counsel & Corp Secty	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Michelle Keefe	officer: Pres., Commercial Solutions	C/O SYNEOS HEALTH,INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jason M. Meggs	officer: Chief Financial Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Donna Hildebrand Kralowetz	officer: SVP, Chief Accounting Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Matthew E. Monaghan	director	ONE INVACARE WAY, ELYRIA OH 44035
Alfonso G Zulueta	director	4925 INDIANA AVE, LISLE IL 60532
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Linda S Harty	director	MEDTRONIC PLC, 710 MEDTRONIC PARKWAY NE, LC-150, MINNEAPOLIS MN 55432
Alistair Macdonald	officer: Chief Operating Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
David S. Wilkes	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Advent International Corp/ma	10 percent owner	800 BOYLSTON STREET SUITE 3300, BOSTON MA 02199